Form D · Biotechnology
Cambrian BioPharma Inc
New York, NY · CIK 0001797409
Offering snapshot reported Jul 15, 2026 · SEC filing
- Reported sold
- $124M Offering amount: $130M
- Investors reported
- 80 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2026 | Initial | $123,751,064 | No comparison | 80 | SEC filing |
| Jan 13, 2025 | Amendment | $23,022,065 | $15,330,232vs Dec 22, 2023 | 30 | SEC filing |
| Dec 22, 2023 | Initial | $7,691,833 | No comparison | 20 | SEC filing |
| Dec 2, 2021 | Initial | $92,209,653 | No comparison | 56 | SEC filing |
| May 6, 2021 | Initial | $28,434,938 | No comparison | 30 | SEC filing |
| Jan 27, 2020 | Initial | $4,750,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-590950
Source: Form D, filed Jul 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christian Angermayer | Director |
| Christian Angermeyer | Director |
| William De Vaul | Executive |
| Paul Farr | Director |
| Martin Gunhaga | Director |
| Juliette Han | Director, Executive |
| Mark Nuttall | Executive |
| James Peyer | Director, Executive |
| Maryanna Saenko | Director |
| Brenton L. Saunders | Director |
| Ruth Thieroff Ekerdt | Executive |
| Lorin Van Nuland | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
228 Park Avenue South Suite 66643
New York, NY, 10003
Phone: (516) 962-3186
New York, NY, 10003
Phone: (516) 962-3186